Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

and NGX426, are the first AMPA/kainate-type glutamate receptor antagonists to be studied in clinical trials. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and NGX426 have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain, muscle spasticity, thrombosis, epilepsy and a condition known as central sensitization, a persistent state of hypersensitivity to pain that is a core component of many pain conditions.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for NGX426 as a treatment for neuropathic pain, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain and the potential for tezampanel and
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 PRC Clinical, ... the San Francisco Bay Area, will exhibit and present ... Conference 2015 on March 25th and 26th in ... build relationships with Israeli life science companies seeking to ... The company’s services span all phases of human trials, ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced the ... August of last year. As part of the acquisition, ... Koo continuing his role as CEO for the ... Vegalab S.A., will work alongside Koo and oversee developments ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin ...
(Date:3/4/2015)... 4, 2015   ... Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für die ... Royal Philips (NYSE: PHG, AEX: PHIA) gab ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Today a promising young,scholar in bioethics, Dr. Jorge ... Award in Bioethics for his proposed research and,its ... Latin America during,the 27th Pan American Sanitary Conference ... the Pan American Health and,Education Foundation (PAHEF), presented ...
... and NUTLEY, N.J., Oct. 1 This month,Med ... business and,marketing publications, selected Roche out of 50 ... This marks the first time Roche has,received this ... focus on innovation-driven,healthcare as demonstrated by its top ...
... - New Product Under Development for the ... 28 European Countries DAIICHI SANKYO EUROPE GmbH has ... antihypertensive medication. It is a fixed combination,(CS-8663) of two ... antagonist Amlodipin. When approved, the new combination for ...
Cached Biology Technology:Prestigious Bioethics Award for Scholar from Mexico 2Med Ad News Honors Roche as 'Company of the Year' 2Med Ad News Honors Roche as 'Company of the Year' 3DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin 2
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... 10, 2011The mega-mergers of 2009 did not continue into 2010. ... price tag of more than $40 billion, only last year,s ... of reported deals conducted by Genetic Engineering & Biotechnology News ... the year, sanofi-aventis, move to buy Genzyme, is still being ...
... reports that several herbicides used on corn also have ... Miscanthus), a potential bioenergy feedstock. "No herbicides are ... biomass," said Eric Anderson, an instructor of bioenergy for ... of Illinois. "Our research shows that several herbicides used ...
... 20,000 to 30,000 genes (the number is hotly contested), but ... proteins. It,s the protein molecules that domost of the work ... from the Greek prota, meaning "of primary importance." Proteins ... of usually fold spontaneously into what is called their "native ...
Cached Biology News:GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Miscanthus has a fighting chance against weeds 2New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
Biology Products: